Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29617604 | 1.00 | KCNH2 (0.42) | KCNH2HTR2CKDM4EALDH1A1POLB | |
| SCHEMBL29087760 | 0.86 | HTR2C (0.45) | HTR2CALDH1A1POLBCHRNB2CHRNA4 | |
| SCHEMBL29087715 | 0.85 | EPHX2 (0.39) | KCNH2KDM4EGAACHRNB2CHRNA4 | |
| SCHEMBL27798006 | 0.85 | P2RY14 (0.45) | KCNH2HTR2CP2RY14CHRNB2CHRNA4 | |
| Acetic Acid SCHEMBL9894871 | 0.84 | PSEN1 (0.44) | KCNH2HTR2CCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL29087674 | 0.84 | ALDH1A1 (0.41) | ALDH1A1CYP2C19CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL8267837 | 0.82 | S1PR4 (0.44) | KCNH2KDM4EALDH1A1POLBGAA | |
| SCHEMBL14984450 | 0.81 | DGAT1 (0.47) | HTR2CKDM4EALDH1A1POLBGAA | |
| SCHEMBL29087734 | 0.81 | SLC6A2 (0.41) | — | |
| SCHEMBL641276 | 0.79 | HTR2C (0.43) | KCNH2HTR2CKDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416202-A1 | Small Molecule Compounds and Compositions | TELO THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
| EP-4247374-A1 | SMALL MOLECULE COMPOUNDS AND COMPOSITIONS | Telo Therapeutics, Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| CN-116710431-A | Small molecule compounds and compositions | 泰洛治疗公司 | 2023-09-05 | — | — | CN | disclosed |
| WO-2022109209-A1 | SMALL MOLECULE COMPOUNDS AND COMPOSITIONS | TELO THERAPEUTICS, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| EP-2435428-B1 | SUBSTITUTED PIPERIDINES | BAYER IP GMBH (DE) | 2013-07-31 | — | — | EP | disclosed |
| US-20120149694-A1 | Substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-14 | — | — | US | disclosed |
| US-20120149694-A1 | Substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-14 | — | — | US | disclosed |
| WO-2010136128-A1 | SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149694-A1 | Substituted piperidines | VHL, PIR, PIGO | KCNH2 517/4885HTR2C 2089/4885KDM4E 3131/4885 |
| US-20230416202-A1 | Small Molecule Compounds and Compositions | TERT, TP53, EP300 | KCNH2 4595/4885HTR2C 3850/4885KDM4E 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.